• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Elscint to market coincidence detection

Article

Israeli medical imaging vendor Elscint is preparing to begin commercialshipments of its Coincidence Detection (CODE) high-energy imagingtechnique after receiving 510(k) clearance from the Food and DrugAdministration last month. Elscint joins ADAC

Israeli medical imaging vendor Elscint is preparing to begin commercialshipments of its Coincidence Detection (CODE) high-energy imagingtechnique after receiving 510(k) clearance from the Food and DrugAdministration last month. Elscint joins ADAC Laboratories andPicker International in being able to market coincidence detection,which is used to image high-energy radioisotopes like fluorodeoxyglucose.

Elscint will offer CODE on its premium variable-angle VariCamgamma camera, with a list price under $200,000, according to RichardBrown, marketing manager at Elscint's U.S. subsidiary in Hackensack,NJ. Elscint is also debating whether to offer CODE to its installedbase of older Helix opposable-angle cameras. Helix cameras wouldhave to be upgraded with new detectors and acquisition racks,however, which might make a CODE upgrade prohibitively expensive.

Elscint will offer CODE in two configurations: CODE 3 employsa 3/8-inch crystal, while CODE 5 uses a 5/8-inch version. Lastmonth's 510(k) clearance applies to CODE 3, and a supplementaryapplication will be filed for CODE 5, according to Brown.

CODE should help increase VariCam sales, which have paced Elscint'snuclear medicine division to record sales levels, according topresident and CEO Jonathan Adereth. CODE will also improve profitmargins in the nuclear medicine line, which in the past has sufferedfrom declining profitability, Adereth said.

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.